S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
Log in
NASDAQ:BLFS

BioLife Solutions Competitors

$39.32
+0.33 (+0.85 %)
(As of 02/26/2021 02:19 PM ET)
Add
Compare
Today's Range
$38.40
Now: $39.32
$40.21
50-Day Range
$37.07
MA: $40.93
$44.24
52-Week Range
$7.37
Now: $39.32
$47.22
Volume7,076 shs
Average Volume278,690 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.55

Competitors

BioLife Solutions (NASDAQ:BLFS) Vs. LIVN, CNMD, INMD, OM, TMDX, and NTUS

Should you be buying BLFS stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to BioLife Solutions, including LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Outset Medical (OM), TransMedics Group (TMDX), and Natus Medical (NTUS).

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares BioLife Solutions and LivaNova's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50
LivaNova$1.08 billion3.49$-155,180,000.00$3.0825.28

BioLife Solutions has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
LivaNova-21.88%5.55%3.07%

Analyst Ratings

This is a summary of recent ratings for BioLife Solutions and LivaNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions02802.80
LivaNova03402.57

BioLife Solutions currently has a consensus target price of $32.4444, indicating a potential downside of 17.49%. LivaNova has a consensus target price of $67.8571, indicating a potential downside of 12.84%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares BioLife Solutions and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
CONMED0.04%9.48%3.75%

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for BioLife Solutions and CONMED, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions02802.80
CONMED02402.67

BioLife Solutions currently has a consensus target price of $32.4444, indicating a potential downside of 17.49%. CONMED has a consensus target price of $104.60, indicating a potential downside of 14.64%. Given CONMED's higher probable upside, analysts plainly believe CONMED is more favorable than BioLife Solutions.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BioLife Solutions and CONMED's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50
CONMED$955.10 million3.71$28.62 million$2.6446.42

CONMED has higher revenue and earnings than BioLife Solutions. CONMED is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats CONMED on 7 of the 13 factors compared between the two stocks.

InMode (NASDAQ:INMD) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares InMode and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
BioLife Solutions12.67%0.53%0.43%

Volatility and Risk

InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for InMode and BioLife Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
BioLife Solutions02802.80

InMode presently has a consensus target price of $71.50, indicating a potential upside of 4.32%. BioLife Solutions has a consensus target price of $32.4444, indicating a potential downside of 17.49%. Given InMode's stronger consensus rating and higher probable upside, equities analysts plainly believe InMode is more favorable than BioLife Solutions.

Institutional and Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares InMode and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million14.02$61.15 million$1.6042.84
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50

InMode has higher revenue and earnings than BioLife Solutions. InMode is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats BioLife Solutions on 10 of the 14 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Institutional and Insider Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Outset Medical and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
BioLife Solutions12.67%0.53%0.43%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Outset Medical and BioLife Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
BioLife Solutions02802.80

Outset Medical presently has a consensus target price of $55.00, indicating a potential upside of 11.40%. BioLife Solutions has a consensus target price of $32.4444, indicating a potential downside of 17.49%. Given Outset Medical's higher probable upside, equities analysts plainly believe Outset Medical is more favorable than BioLife Solutions.

Earnings and Valuation

This table compares Outset Medical and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50

Outset Medical has higher earnings, but lower revenue than BioLife Solutions.

Summary

BioLife Solutions beats Outset Medical on 7 of the 9 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for TransMedics Group and BioLife Solutions, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
BioLife Solutions02802.80

TransMedics Group presently has a consensus price target of $24.00, indicating a potential downside of 30.82%. BioLife Solutions has a consensus price target of $32.4444, indicating a potential downside of 17.49%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than TransMedics Group.

Earnings & Valuation

This table compares TransMedics Group and BioLife Solutions' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million39.92$-33,550,000.00($2.36)-14.70
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50

BioLife Solutions has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 22.3% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares TransMedics Group and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
BioLife Solutions12.67%0.53%0.43%

Summary

BioLife Solutions beats TransMedics Group on 11 of the 14 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioLife Solutions and Natus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions02802.80
Natus Medical01002.00

BioLife Solutions currently has a consensus price target of $32.4444, indicating a potential downside of 17.49%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Natus Medical.

Earnings and Valuation

This table compares BioLife Solutions and Natus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million47.03$-1,660,000.00$0.08491.50
Natus Medical$495.52 million1.78$-15,670,000.00$1.2421.06

BioLife Solutions has higher earnings, but lower revenue than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 1.5% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Natus Medical-4.33%3.87%2.50%

Summary

BioLife Solutions beats Natus Medical on 8 of the 14 factors compared between the two stocks.


BioLife Solutions Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LivaNova logo
LIVN
LivaNova
1.5$77.85+1.5%$3.73 billion$1.08 billion-18.10Earnings Announcement
Analyst Upgrade
CNMD
CONMED
1.6$122.54+0.1%$3.54 billion$955.10 million-3,063.50Dividend Announcement
Insider Selling
INMD
InMode
1.5$68.54+2.0%$2.15 billion$156.36 million49.31Analyst Upgrade
OM
Outset Medical
0.7$49.37+0.4%$2.12 billionN/A0.00Upcoming Earnings
TMDX
TransMedics Group
1.2$34.69+6.3%$1.00 billion$23.60 million-24.78Upcoming Earnings
Analyst Report
Gap Up
NTUS
Natus Medical
1.1$26.11+0.3%$881.92 million$495.52 million-47.47Earnings Announcement
News Coverage
AxoGen logo
AXGN
AxoGen
1.3$21.99+2.1%$874.53 million$106.71 million-34.90Earnings Announcement
Analyst Report
ViewRay logo
VRAY
ViewRay
1.3$4.37+2.5%$665.28 million$87.78 million-4.91Upcoming Earnings
News Coverage
Gap Down
Cutera logo
CUTR
Cutera
1.3$36.28+1.5%$629.85 million$181.71 million-20.04Analyst Upgrade
Gap Down
ZYXI
Zynex
1.7$14.26+22.2%$605.19 million$45.47 million43.21Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
Edap Tms logo
EDAP
Edap Tms
1.3$9.03+5.6%$276.66 million$50.23 million-150.50News Coverage
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$2.47+2.4%$201.43 millionN/A-3.25Upcoming Earnings
Gap Down
BSGM
BioSig Technologies
1.2$4.58+2.6%$137.01 millionN/A0.00Upcoming Earnings
FONR
FONAR
1.0$19.86+1.3%$128.52 million$85.69 million18.74
ECOR
electroCore
1.2$2.35+9.4%$96.82 million$2.39 million-2.97Gap Down
NDRA
ENDRA Life Sciences
0.6$2.32+6.0%$92.46 million$10,000.00-1.26Gap Up
IRIDEX logo
IRIX
IRIDEX
0.9$5.83+2.9%$83.39 million$43.45 million-10.60Gap Up
Second Sight Medical Products logo
EYES
Second Sight Medical Products
1.5$1.82+1.6%$42.77 million$3.38 million-0.95
HSDT
Helius Medical Technologies
1.0$13.38+3.1%$31.89 million$1.50 million-0.77
CHF Solutions logo
CHFS
CHF Solutions
1.7$7.70+1.7%$21.42 million$5.51 million-0.15Upcoming Earnings
Digirad logo
DRAD
Digirad
1.4$3.62+15.5%$17.23 million$114.18 million-1.15Upcoming Earnings
Gap Down
STRR
Star Equity
0.1$3.45+4.9%$17.23 million$114.18 million-1.10Upcoming Earnings
Gap Up
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.43+7.6%$7.99 million$6.57 million-0.01
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.